TCM
AMLX icon

Tekla Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Tekla Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$2.24M Buy
+104,007
New +$2.81M 0.09% 110

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Tekla Capital Management's AMLX Position: Q2 2023 in Review

Tekla Capital Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2023: 104,007 shares worth $2.24M. The stake represents 0.09% of the portfolio and ranks #110 among its holdings.

154 funds tracked by Wall St. Rank hold AMLX as of Q2 2023.

  • Tekla Capital Management held 104,007 shares of Amylyx Pharmaceuticals worth $2.24M as of Q2 2023.
  • Amylyx Pharmaceuticals was a new Tekla Capital Management position in Q2 2023.
  • Amylyx Pharmaceuticals made up 0.09% of Tekla Capital Management's portfolio in Q2 2023, its #110 holding.
  • 154 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.